RxDoctor Payments Data

Jackeline Conde, APRN

Family · Port Saint Lucie, FLNPI 1063018133

Payments from drug & device makers

$2,040in general payments, 2019–2025

Across 92 payments — averaging $22.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$479
  • Novartis$307
  • Boehringer Ingelheim$247
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$137
  • Cvrx, Inc.$128
  • Medtronic$120
  • plus $621 from 11 others

What the payments were for

  • Food & beverage$2,040100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,040 in reported general payments places this provider in the 80th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$18,594
Medicare patients
98
Services billed
247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan69$46,711
EliquisApixaban21$23,224
XareltoRivaroxaban13$12,675
Metoprolol Succinate151$1,147
ClopidogrelClopidogrel Bisulfate39$484
Amlodipine Besylate74$404
Losartan Potassium99$346
Isosorbide Mononitrate ErIsosorbide Mononitrate15$246
Metoprolol Tartrate54$235
Hydralazine Hcl28$231
Atorvastatin Calcium21$204
Carvedilol39$187
Hydrochlorothiazide26$119
Lisinopril32$110
Furosemide15$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$307$46,71169 claims
PfizerEliquis$39$23,22421 claims
Johnson & JohnsonXarelto$479$12,67513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 14,618 family providers in Florida.

Other family in Port Saint Lucie

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →